Skip to main navigation Skip to search Skip to main content

Immunological monitoring in patients with end-stage renal disease

  • Wayne C. Waltzer
  • , Radoslav J. Bachvaroff
  • , Audrey P. Raisbeck
  • , Bjorg Egelandsdal
  • , Christopher Pullis
  • , Liling Shen
  • , Felix T. Rapaport
  • Stony Brook University

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Parameters of cell-mediated immune function were determined in 76 patients with end-stage renal disease. Lymphocyte subpopulations (OKT3, OKT4, OKT8, OKIal, OKM1, OKT9, OKT10), natural killer (NK)-cell activity (percentage51Cr release from K562 targets), and delayed cutaneous hypersensitivity were measured and correlated with other variables. The results indicate that (1) uremic patients have a significant diminution in the OKT4-lymphocyte subpopulation and OKT4/OKT8 (helper/suppressor) ratio compared to normal controls; (2 blood transfusions do not induce significant alterations in the helper/suppressor-cell ratio; (3) uremic patients have a significant increase in OKM1 cells compared to normal controls; (4) the majority of uremic patients in this series developed delayed cutaneous hypersensitivity responses to recall antigens and could be de novo sensitized to 2,4-dinitrochlorobenzene (DNCB); (5) skin-test reactivity could not be correlated with total circulating T cells or levels of any lymphocyte subpopulations; and (6) NK-cell activity in uremic patients is not significantly different from that in normal controls. These results highlight the varying levels and function of different lymphocyte subsets in patients with end-stage renal disease when they are treated with chronic maintenance hemodialysis.

Original languageEnglish
Pages (from-to)364-368
Number of pages5
JournalJournal of Clinical Immunology
Volume4
Issue number5
DOIs
StatePublished - Sep 1984

Keywords

  • end-stage renal disease
  • Immune monitoring

Fingerprint

Dive into the research topics of 'Immunological monitoring in patients with end-stage renal disease'. Together they form a unique fingerprint.

Cite this